LC-MS/MS comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-02-07. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule ligand; not a hormone or peptide |
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| CAS Registry Number | 1379686-30-2 | Unique chemical identifier |
| Common synonyms | SR9009; stenabolic | Stenabolic is informal and not an official name |
| Reported targets | REV-ERBα and REV-ERBβ | Nuclear receptors linked to circadian and metabolic regulation |
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
=== 1995–2006: DNA identity testing === In 1995, Bio-Synthesis, Inc. introduced DNA identity testing to its broad range of molecular diagnostic services. Today, the DNA Identity Testing Center of BSI uses advanced techniques and automated systems to produce the most accurate DNA testing results allowed by current scientific technologies. The DNA Identity Testing Center has its own staff of scientific professionals whose focus is to ensure the quality and integrity of all tests and services. In 2000, Bio-Synthesis, Inc. perform the genetic analysis close to 500 Chinese nationals that were soliciting, under the right of abode, the right to move to Hong Kong by proving that their biological fathers were Hong Kong residents.
== Production and styles == Meat floss is made by stewing lean meat finely cut along the grain in a broth until the meat is very tender and individual muscle fibers can be teased apart. This happens when the water-insoluble collagen that holds the muscle fibers of the meat together has been converted into water-soluble gelatin. The meat is then separated from the broth and shredded into fibrous strips. It is then added back into the broth which is enriched with soy sauce, sugar, fennel, ginger, rice wine or other ingredients. The mixture is then cooked at low heat and stirred continuously until the floss is dried. There are different regional styles of meat floss, which differ in whether oil is added during the last process of production. Jiangsu style rousong is dry-cooked and the product is slightly chewy, while Fujian style bak hu is fried with oil and the product is mildly crispy. Five kilograms (11 lb) of meat will usually yield about one kilogram (2.2 lb) of floss. Taiwanese pork floss is made by cutting pork along the muscle fibers then boiling it for around 80 minutes to reduce moisture and soften collagen. The meat is then pressed into a paddle to loosen fibers, then transferred to a gas-fired frypan with mechanical scrapers to aid in drying and reducing the meat into long fibers. Sucrose, dehydrated starch and salt is then added at a specific time and ratio to enhance flavor and texture without hindering moisture removal. Once the desired consistency and dryness is obtained, the floss is stored briefly at room temperature and reheated in the scraping-frypan.
Sirius Red F 3B (Direct Red 80) is an azo dye primarily used in staining methods for collagen and amyloid. It has the molecular formula C45H26N10Na6O21S6. In histology, sirius red staining is used in various domains of diagnostic to observe fibrosis levels in a lot of cases of inflammation induced by cancer, vascular or metabolic pathologies. In bright-field microscopy the following can be observed:
== Approvals and clinical trials == In Germany, CXL has been used in patients with keratoconus since 1998, and in Italy, routine interventions have been successfully performed since 2005. The standard (Dresden) CXL protocol with epithelium removal, is approved for use throughout Europe. In the United States, clinical trials commenced only in 2008. Based on three 12-month clinical trials, the US Food and Drug Administration approved riboflavin ophthalmic solution and Avedro's KXL system for crosslinking on 18 April 2016, for the treatment of progressive keratoconus, and on 19 July 2016, for corneal ectasia after refractive surgery, making them the first FDA approved treatment for keratoconus and post-LASIK ectasia.
Sources: en.wikipedia.org
== Pharmacology == Nateglinide lowers blood glucose by stimulating the release of insulin from the pancreas. It achieves this by closing ATP-dependent potassium channels in the membrane of the β cells. This depolarizes the β cells and causes voltage-gated calcium channels to open. The resulting calcium influx induces fusion of insulin-containing vesicles with the cell membrane, and insulin secretion occurs.
Hussein al-Houthi believed that the "last exemplary" Zaydi scholar and leader was Al-Hadi ila'l-Haqq Yahya; later Zaydi imams were regarded as having deviated from the original form of Islam. The Houthis' belief in the "Quranic Way" also includes the rejection of tafsir (Quranic interpretations) as being derivative and divisive, meaning that they have a low opinion of most existing Islamic theological and juridical schools, including Zaydi traditionalists based in Sanaa with whom they often clash. The Houthis claim that their actions are to fight against the alleged expansion of Salafism in Yemen and for the defence of their community from discrimination. The position of Saudi-backed Salafis and other Sunni groups in Yemen had steadily increased throughout the Republican era, as did the position of Sheikhs who sometimes cooperated with these Salafi groups for pragmatic reasons. The Salafis, who enjoyed considerable support from the Saleh regime, reportedly pursued an aggressive "policy of provocation" towards the Zaydis who inhabited the surrounding area, often accusing them of apostasy. In the years before the rise of the Houthi movement, state-supported Salafis had harassed Zaydis and destroyed Zaydi sites (most notably cemeteries) in Yemen. After their rise to power in 2014, the Houthis consequently "crushed" the Salafi community in Saada Governorate and mostly eliminated the al-Qaeda presence in the areas under their control; the Houthis view al-Qaeda as "Salafi jihadists" and thus "mortal enemies".
=== Trials of drugs === Some clinical trials involve healthy subjects with no pre-existing medical conditions. Other clinical trials pertain to people with specific health conditions who are willing to try an experimental treatment. Pilot experiments are conducted to gain insights for design of the clinical trial to follow. There are two goals to testing medical treatments: to learn whether they work well enough, called "efficacy", or "effectiveness"; and to learn whether they are safe enough, called "safety". Neither is an absolute criterion; both safety and efficacy are evaluated relative to how the treatment is intended to be used, what other treatments are available, and the severity of the disease or condition. The benefits must outweigh the risks. For example, many drugs to treat cancer have severe side effects that would not be acceptable for an over-the-counter pain medication, yet the cancer drugs have been approved since they are used under a physician's care and are used for a life-threatening condition. In the US the elderly constitute 14% of the population, while they consume over one-third of drugs. People over 55 (or a similar cutoff age) are often excluded from trials because their greater health issues and drug use complicate data interpretation, and because they have different physiological capacity than younger people. Children and people with unrelated medical conditions are also frequently excluded. Pregnant women are often excluded due to potential risks to the fetus.
Sources: en.wikipedia.org
The surgeon-in-chief of Napoleon's army at the Siege of Alexandria (1801), Baron Dominique-Jean Larrey, wrote in his memoirs that the consumption of horse meat helped the French to curb an epidemic of scurvy. The meat was cooked but was freshly obtained from young horses bought from Arabs, and was nevertheless effective. This helped to start the 19th-century tradition of horse meat consumption in France. Lauchlin Rose patented a method used to preserve citrus juice without alcohol in 1867, creating a concentrated drink known as Rose's lime juice. The Merchant Shipping Act 1867 required all ships of the Royal Navy and Merchant Navy to provide a daily "lime or lemon juice" ration of one pound to sailors to prevent scurvy. The product became nearly ubiquitous, hence the term "limey", first for British sailors, then for English immigrants within the former British colonies (particularly America, New Zealand, and South Africa), and finally, in old American slang, all British people. The plant Cochlearia officinalis, also known as "common scurvygrass", acquired its common name from the observation that it cured scurvy, and it was taken on board ships in dried bundles or distilled extracts. Its bitter taste was usually disguised with herbs and spices; however, this did not prevent scurvygrass drinks and sandwiches from becoming a popular fad in the UK until the middle of the nineteenth century, when citrus fruits became more readily available.
Natural Selection was one of the first multiplayer, first-person shooters to incorporate a "Commander", whose view of the battlefield was essentially 2-D, from a strictly top-down perspective. One member of the marine team must enter the "command chair" to lead the team, and thus become the "Commander". From here, he can purchase upgrades, issue movement orders and drop supplies - all from an overhead perspective, as in many RTS games. The commander can also place buildings, although these are inactive until built by players in the field. The alien team has no defined leader, and so it must communicate and co-operate to ensure different roles are fulfilled as needed. There is only one "Builder Class", the Gorge which can be used to build a multitude of structures. Gorges can choose to build three different "upgrade" chambers: Movement, Defense, and Sensory, each providing three distinct abilities each alien can get. Gorges can also build Offense chambers which damage Marines from a distance, and resource towers. When a resource nozzle is capped, the resources gained are split evenly among all aliens. Each alien can choose how he wants to use his own personal reserve of resource points : building structures (as a gorge), or gestating into higher lifeforms. On death of the lifeform or structure, there is no refund on the resource points spent. Kharaa "Hive Sight" reveals teammates through the walls and structures of the map, this was originally their answer to the commander with his top-down overview of the game.
=== Polymeric micelles === Polymeric micelles are drug carriers formed by the aggregation of some amphiphile\amphiphilic molecule with an amphiphilic block copolymer. These carriers form at some high concentration specific to the compounds used, called the critical micelle concentration. The addition of an amphiphilic block copolymer effectively lowers this critical micelle concentration by shifting the monomer exchange equilibrium. These carriers are comparable to liposomes, however the lack of an aqueous core makes polymeric micelles less accommodating to a wide variety of drugs.
Sources: en.wikipedia.org
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.
No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.
Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.